Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 5/20 | 0.52 |
| ▸ | HTR1B | P28222 | 4/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945372 | 0.93 | SMN1; SMN2 (0.52) | HTR1DHTR1BHTR1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5529129 | 0.91 | HTR1D (0.52) | HTR1DHTR1BHTR1ASMN1; SMN2NCF1 | |
| SCHEMBL5532963 | 0.89 | NCF1 (0.58) | HTR1DHTR1BHTR1ASMN1; SMN2ROCK1 | |
| SCHEMBL13945359 | 0.89 | HTR1D (0.51) | HTR1DHTR1BHTR1ASMN1; SMN2NCF1 | |
| SCHEMBL5531973 | 0.88 | HTR1D (0.50) | HTR1DHTR1BHTR1ASMN1; SMN2ROCK1 | |
| SCHEMBL8087949 | 0.85 | SCN1A (0.45) | HTR1DHTR1BHTR1ASMN1; SMN2ROCK1 | |
| SCHEMBL14437441 | 0.83 | NCF1 (0.51) | HTR1DHTR1BHTR1ASMN1; SMN2ROCK1 | |
| SCHEMBL5529815 | 0.83 | NCF1 (0.51) | HTR1DHTR1BHTR1ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5532956 | 0.83 | MCHR1 (0.53) | HTR1DHTR1BHTR1ASMN1; SMN2ROCK1 | |
| SCHEMBL5532724 | 0.82 | SMN1; SMN2 (0.49) | HTR1DHTR1BHTR1ASMN1; SMN2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | HTR1D 483/4885HTR1B 354/4885HTR1A 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.